Nano Miscellaneous
Market Cap
₹39 ₹39.00 Cr.
P/E
5.38
PEG = P/E ÷ 5yr forward EPS CAGR

The forward EPS CAGR is estimated individually for each company - factoring in its guidance, industry, and growth drivers - not generic rule-based projection.

Key Ratios

Debt to Equity
Debt to Equity
0.13
Div Yield (%)
Div Yield (%)
-
Individual < 2 lac
Individual < 2 lac
19.11 %
Institutions
Institutions
-
Market cap
Market cap
39.00 Cr
No. of Shareholders
No. of Shareholders
454
OPM (%)
OPM (%)
10.60 %
PE
PE
5.38
Prom Holding
Prom Holding
62.24 %
ROCE (%)
ROCE (%)
32.03
ROE (%)
ROE (%)
22.83
Sales
Sales
103 Cr
  • Royal Sense
  • Alfavision Overseas
  • Nanavati Ventures
Last updated on 5 Oct 2026
  • Royal Sense trades and distributes pharma and medical products and owns no manufacturing. Most of its revenue runs through the wholly-owned subsidiary Stergic Retail.
  • Its branded portfolio spans Stergivita (multivitamins), Lycoseven (an antioxidant), Dermagic (derma range), Sterpidem (a prescription sleep medicine) and a BP Monitor device.
  • Set up in 2023 as a trader and listed on BSE SME in April 2024, it is now shifting toward its own branded products.
  • Stergic Retail is about 64% of consolidated revenue, so the subsidiary drives results. Margins are thin, at about 7% PAT in FY26.
  • Seventeen own-brand products launched in April 2026 and are on sale domestically. Management aims to deepen penetration and explore exports, per its FY25 annual report.
  • Working capital is the strain: receivables rose 96% and inventory 151% in FY26, and operating cash flow turned negative. Recurring warrant issues fund the gap.
  • Near-term profit depends on how fast the new brands sell and on Stergic Retail's continued growth. Any stall exposes the working-capital strain.
  • A governance overhang persists: a related party supplied over half of FY25 purchases, and the promoter pledged 18.69% of shares in September 2026.
  • AGM vote on managing director re-appointment was 28 Sep 2026; no update since
    the promoter's reappointment for three years as managing director awaits shareholder approval.
  • First branded-product sales in H1FY27 results ~15 Nov 2026
    the first period that can show sales of the 17 April launches, alongside receivables, inventory and cash-flow trends.
  • Remaining warrant conversions no stated timeline
    ₹2.5Cr remains payable against warrants; conversion adds dilution on top of the FY25 and FY26 issues.
  • Related-party purchase limits ongoing
    purchases from TTG Innovations were ~56% of FY25 purchases; changes in limits or terms affect pricing and independence.
Price Range

See where the stock is trading versus its 52-week high and low.

Low
68
52W Range
High
256
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

10 Yes

Positive for this company

2 Neutral

Neutral for this company

2 No

Negative for this company

3 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Peer Comparison

FAQs on Royal Sense Ltd. Business

Royal Sense is engaged in dealing in and providing a large selection of surgical supplies, tools, equipment, and other things. The supplied range may be modified to meet the demands of the clients and is offered in a variety of parameters. It works relentlessly with the right strategy, forward thinking and progressive ethos to position itself as the one-stop solution for customers looking to meet their complete needs for medical equipment, surgical instruments, surgical consumables, laboratory equipment, laboratory reagents, medical consumables, diagnostic equipment, sanitary napkins, pharmaceuticals, medicine and cosmetics.

Royal Sense major competitors are Future Consumer, Tavexia Lifecare, Ecofinity Atomix, Aeonx Digital Techno, Danube Industries, ABM International, Ramgopal Polytex.
Market Cap of Royal Sense is ₹47 Crs.
While the median market cap of its peers are ₹45 Crs.

Royal Sense seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

Company Filing

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
Earnings Release
Investor Presentation
Conference Call
Conference Call SummaryCon Call Summary

Discussions & Analysis

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material